Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4

3(60.0%)

Phase 2

1(20.0%)

N/A

1(20.0%)

5Total

Phase 4(3)

Phase 2(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07352917Phase 2Recruiting

Methotrexate for Severe Vulvar Lichen Sclerosus

Role: lead

NCT06079645Not ApplicableCompleted

Lichen Sclerosus - Treatment With Triamcinolone Acetonide: Injections (Syringe and Needle) x Micro Injections (MMP Technique)

Role: lead

NCT06110377Phase 4Unknown

MALE HAIR LOSS - Treatment With Dutasteride Mesotherapy x Dutasteride MMP Technique (Injections With Tattoo Machine)

Role: lead

NCT04046679Phase 4Unknown

Bleomycin Infusion (MMP®) to Repigment Achromic Scars

Role: lead

NCT02904564Phase 4Unknown

Conventional Microneedling vs Microneedling With 5-FU (MMP) for Idiopathic Guttate Hypomelanosis (IGH) Repigmentation

Role: lead

All 5 trials loaded